

**CURRICULUM VITAE****DAVID A. GARCIA, MD****PERSONAL DATA**

Born: St. Louis, MO  
 Citizenship: USA  
 DOB: May 5, 1967

**EDUCATION**

M.D., University of Alabama School of Medicine	1989 – 1993
B.A. in physics; magna cum laude, Duke University	1985 – 1989

**POSTGRADUATE TRAINING**

Internship and residency, Internal Medicine The Johns Hopkins Hospital	7/1993 – 6/1996
Fellowship, Division of Hematology University of Washington	12/2012 – 12/2013

**FACULTY POSITIONS HELD**

Acting Instructor, Department of Internal Medicine Johns Hopkins Hospital	7/1998 – 6/1999
Assistant/Associate Professor, Division of General Internal Medicine University of New Mexico	9/1999 – 6/2008
Associate Professor, Division of Hematology/Oncology University of New Mexico	7/2008 – 6/2012
Professor, Division of Hematology/Oncology University of New Mexico	6/2012 – 11/2012
Professor, Division of Hematology University of Washington	7/2013 - present

**HOSPITAL POSITIONS HELD**

Hospitalist for Mid-Atlantic Permanente Medical Group at Holy Cross Hospital (Silver Spring, MD)	7/1996 – 5/1998
---	-----------------

**HONORS**

Phi Beta Kappa, Duke University	1988
Alpha Omega Alpha, University of Alabama School of Medicine	1992
House-staff Teaching Award, Johns Hopkins Hospital	1996
DoIM Faculty Teaching Award, University of New Mexico	2005

**BOARD CERTIFICATION**

Internal Medicine (through 2016)  
Hematology (through 2024)

**CURRENT LICENSE(S) TO PRACTICE**

Washington (through May 2025)  
Idaho (through June 2024)

**PROFESSIONAL ORGANIZATIONS**

Member, American Society of Hematology  
Member, International Society of Thrombosis and Hemostasis

**TEACHING RESPONSIBILITIES**

Tutorial group faculty leader, Evidence-based Medicine Course University of New Mexico	2010 – 2012
Assistant Course Director, Hematology Course (2 <sup>nd</sup> Year Medical Students) University of Washington	2014 – 2016
Faculty Member, ASH Clinical Research Training Institute	2012 – 2014; 2016 – 2018
Co-Director, ASH Clinical Research Training Institute	2017- 2018
Associate Prog. Director, UW/FHCC Hematology Fellowship	2022 - present

**EDITORIAL RESPONSIBILITIES**

Contributing Editor, <i>The Hematologist</i>	2014 - 2016
Special Section Editor for Evidence-based Focused Reviews, <i>Blood</i>	2014 - 2017
Associate Editor, ACP Journal Club	2009 – 2014
Editorial Board Member, <i>Thrombosis Research</i>	2003 – present
Editorial Board Member, <i>Journal of Thrombosis and Haemostasis</i>	2013 – present
Editorial Board Member, <i>Journal of Thrombosis and Thrombolysis</i>	2017 - 2021

**SPECIAL NATIONAL RESPONSIBILITIES**

President, Anticoagulation Forum	2007 – 2013
Chairman of the inaugural Thrombosis and Hemostasis Summit of North America (Chicago)	May 2012
Co-Chair, Thrombosis and Hemostasis Summit of North America (Chicago)	April 2014

<i>Ex officio</i> Member, Board of Directors of Anticoagulation Forum	2007 – 2022
Secretary, National Association for Thrombosis and Hemostasis	2012 – 2016
Member, Board of Directors of Thrombosis and Hemostasis Societies of North America	2014 – 2017
Member, ASH Clinical Research Training Inst. Oversight Cmte	2014 – 2019
Member, ASH Scientific Cmte: Thrombosis and Vascular Biology	2013 - 2016
Chair, ASH Special Session on Systems-based Hematology	2016
Chair, ASH Scientific Cmte: Thrombosis and Vascular Biology	2016 – 2017
Education Co-Chair, ASH Annual Meeting	2022

### **SPECIAL LOCAL RESPONSIBILITIES**

Associate Medical Director, Antithrombotic Therapy University of Washington Medical Center	7/29/13-present
Assistant Course Director, Hematology Course for 2 <sup>nd</sup> -year students University of Washington School of Medicine	8/1/13 – 7/1/16
Director, Undergraduate Medical Education Department of Internal Medicine University of New Mexico Health Sciences Center	10/23/06–7/30/08
Medical Director, Inpatient Internal Medicine University of New Mexico Hospital	10/15/00–6/30/07

**RESEARCH FUNDING**Current:

Incyte: INCB-MA-MF-401

06/12/2017 – 2023

“Prospective, longitudinal, non-interventional, study of a low-risk adult population with either Myelofibrosis or Essential Thrombocythemia (ET) who are receiving ET-directed therapy.”

Role: Local PI

Incyte: INCB-MA-PV-401

11/25/2015 – 2023

“Prospective, observational study of an adult population who with clinically Polycythemia Vera.”

Role: Local PI

Past:

Principal Investigator for approximately 20 clinical trials (sponsored by industry, NHLBI, CIHR, PCORI) between 2001 and 2020.

**BIBLIOGRAPHY**

please click [here](#) to see a real-time list of publications by David A. Garcia

**Peer-reviewed publications** (\*- denotes the five most significant publications)

1. Libby E, **Garcia, D.** A survey of Vitamin K use by anticoagulation clinics. *Arch Int Med.* 162(16): 1893-189, 2002
2. **Garcia D,** Ageno W, Libby E, Bibb J, Douketis J, Crowther M. Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice. *J Thromb Thrombolysis.* 18(3): 199-203; 2004
3. Ageno W, **Garcia D,** Libby E, Crowther M. Managing oral anticoagulant therapy in patients with mechanical heart valves undergoing elective surgery: results of a survey conducted among Italian physicians. *Blood Coagul Fibrinolysis* 15:623-628; 2004
4. **Garcia D,** Libby E, Rich JS. Perioperative anticoagulation for patients with mechanical heart valves: a model comparing unfractionated and low molecular weight heparin. *J Clin Outcomes Management* 12:25-32; 2005
5. Oh D, Kim S, Lim CY, Lee JS, Park S, **Garcia D,** Crowther MA, Ageno W. Perioperative anticoagulation in patients with mechanical heart valves undergoing elective surgery: results of a survey conducted among Korean physicians. *Yonsei Med J.* 46(1):66-72; 2005
6. Crowther MA, Ageno W, Schnurr T, Manfredi E, Kinnon K, **Garcia D,** Douketis JD. Oral vitamin K produces a normal INR within 24 hours of its administration in most patients discontinuing warfarin. *Haematologica.* 90(1):137-9, 2005

7. Ageno W, **Garcia D**, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1 mg oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. *J Am Coll Cardiol.* 46(4):732-3; 2005
8. Libby EN, Booker JK, Gulley ML, **Garcia D**, Moll S. False negative factor V leiden genetic testing in a patient with recurrent deep venous thrombosis. *Am J Hematol.* 81(4):284-9; 2006
9. **Garcia D**, Ageno W, Libby E. An update in the diagnosis and treatment of pulmonary embolism. *Br J Hematol.* 131:301-312; 2005
10. \***Garcia D**, Regan S, Crowther M, Hylek E. The risk of hemorrhage among patients with warfarin-associated coagulopathy. *J Am Coll Cardiol.* 47(4): 804-808; 2006
11. Imberti D, Ageno W, Dentali F, Pierfranceschi M, Croci E, **Garcia D**. Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of LMWH to avoid urgent ultrasonographic evaluation. *J Thrombosis Hemostasis.* 4: 1037-41; 2006
12. **Garcia D**, Khamashta MA, Crowther MA. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. *Blood.* 110:3122-3127; 2007
13. \***Garcia D**, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. *Arch Intern Med.* 168(1):63-9; 2008
14. **Garcia D**, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE. Delivery of optimized anticoagulant therapy: consensus statement from the anticoagulation forum. *Ann Pharmacother.* 42(7):979-88, 2008
15. Clark NP, Witt DM, Delate T, Trapp M, **Garcia D**, Ageno W, Hylek EM, Crowther MA. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. *Pharmacotherapy.* 28(8):960-7, 2008
16. Neal M, Crowther M, Douketis J, Verhovsek M, Stidley C, **Garcia D**. Reversal of vitamin K antagonist-associated coagulopathy: a survey of current practice. *Thromb Res.* 122(6):864-6, 2008
17. \*Crowther M, Ageno W, **Garcia D**, Wang L, Witt D, and others. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. *Ann Intern Med.* 150:293-300, 2009
18. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, **Garcia D**, Ageno W, Hylek EM. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. *Blood* 114(5):952-6, 2009
19. Fekrazad MH, Lopes RD, Stashenko GJ, Alexander JH, **Garcia D**. Treatment of venous thromboembolism: guidelines translated for the clinician. *J Thromb Thrombolysis.* 28(3):270-5, 2009
20. Kangelaris K, Bent S, Nussbaum R, **Garcia D**, Tice J. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. *J Gen Intern Med.* 24(5):656-64, 2009
21. **Garcia DA**, Highfill J, Finnerty K, Varoz E, McConkey S, Hutchinson K, Libby E. A prospective, controlled trial of a pharmacy-driven alert system to increase thromboprophylaxis rates in medical inpatients. *Blood Coagul Fibrinolysis.* 20(7):541-5, 2009
22. Ageno W, **Garcia D**, Aguilar MI, Douketis J, Finazzi G, Imberti D, Iorio A, Key NS, Lim W, Marietta M, Prisco D, Sarode R, Testa S, Tosoletto A, Crowther M. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 2: Treatment. *Am J Hematol.* 84(9):584-8, 2009

23. **Garcia D**, Ageno W, Bussey H, Eikelboom J, Margaglione M, Marongiu F, Moia M, Palareti G, Pengo V, Poli D, Schulman S, Witt D, Wittkowsky A, Crowther M. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. *Am J Hematol.* 84(9):579-83, 2009
24. Dentali F, Ageno W, Witt D, Malato A, Clark N, **Garcia D**, McCool K, Siragusa S, Dyke S, Crowther M; for the WARPED consortium. Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists. A multi-centre, retrospective cohort study. *Thromb Haemost.* 102(3):501-504, 2009
25. Witt DM, Delate T, McCool KH, Dowd MB, Clark NP, Crowther MA, **Garcia DA**, Ageno W, Dentali F, Hylek EM, Rector WG; on behalf of the WARPED Consortium. Incidence and predictors of bleeding or thrombosis following polypectomy in patients receiving and not receiving anticoagulation therapy. *J Thromb Haemost.* 7(12):1982-9, 2009
26. \***Garcia D**, Libby E, Crowther MA. The new oral anticoagulants. *Blood.* 115(1):15-20, 2010
27. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, **Garcia DA**, Ageno W, Hylek EM; Warped Consortium. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. *J Thromb Haemost.* 8(4):744-9, 2010
28. **Garcia D**, Crowther MA, Ageno W. Practical management of coagulopathy associated with warfarin. *BMJ.* 19;340:c1813, 2010
29. Winters J. and **Garcia D**. Cancer-associated thrombosis. *Hematol Oncol Clin N Am.* 24:695–707, 2010
30. **Garcia DA**, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. *Thromb Haemost.* 104(6):1099-105, 2010
31. **Garcia D**, Crowther MA, Ageno W. Practical treatment of warfarin associated coagulation disorder. *Praxis (Bern 1994).* 99(25):1569-73, 2010
32. Eagle KA, Cannom DS, **Garcia DA**. Management of atrial fibrillation: translating clinical trial data into clinical practice. *Am J Med.* 124(1):4-14, 2011
33. Stashenko G, Lopes RD, **Garcia D**, Alexander JH, Tapson VF. Prophylaxis for venous thromboembolism: guidelines translated for the clinician. *J Thromb Thrombolysis.* 31(1):122-32, 2011
34. **Garcia DA**, Schwartz MJ. Warfarin therapy: tips and tools for better control. *J Fam Pract.* 60(2):70-5, 2011
35. Burnett A, D'Angio R, Earl LE, **Garcia D**. Challenges and benefits of an inpatient anticoagulation service: one hospital's experience. *J Thromb Thrombolysis.* 31(3):344-52, 2011
36. Dentali F, Donadini MP, Clark N, Crowther MA, **Garcia D**, Hylek E, Witt DM, Ageno W. Brand name versus generic warfarin: a systematic review of the literature. *Pharmacotherapy.* 31(4):386-93, 2011
37. Moualla H, **Garcia D**. Vitamin K antagonists - current concepts and challenges. *Thromb Res.* 128(3):210-5, 2011
38. Martinez L, Burnett A, Borrego M, Streeter JC, Townsend K, **Garcia D**. Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. *Am J Health Syst Pharm.* 68(18):1716-22, 2011
39. \*Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, **Garcia D**, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 365(11):981-92, 2011

40. Lopes RD, Horowitz JD, **Garcia DA**, Crowther MA, Hylek E. Warfarin and acetaminophen interaction: a summary of the evidence and biological plausibility. *Blood*. 118(24):6269-73, 2011
41. **Garcia D**, Quintana D. Thrombosis and malignancy: a case-based review. *Semin Hematol*. 48(4):259-63, 2011
42. **Garcia DA**. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. *Thromb Res*. 129(1):9-16, 2012
43. Alberts MJ, Bernstein RA, Naccarelli GV, **Garcia DA**. Using Dabigatran in patients with stroke: a practical guide for clinicians. *Stroke* 43(1):271-9, 2012
44. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, **Garcia D**, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. *Thromb Haemost*. 106(3):429-38, 2011
45. **Garcia DA**, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: *American College of Chest Physicians Evidence-Based Clinical Practice Guidelines*. *Chest*. 141(2 Suppl):e24S-43S, 2012
46. \*Gould MK, **Garcia DA**, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: *American College of Chest Physicians Evidence-Based Clinical Practice Guidelines*. *Chest*. 141(2 Suppl):e227S-77S, 2012
47. Guyatt GH, Eikelboom JW, Gould MK, **Garcia DA**, Crowther M, Murad MH, Kahn SR, Falck-Ytter Y, Francis CW, Lansberg MG, Akl EA, Hirsh J. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: *American College of Chest Physicians Evidence-Based Clinical Practice Guidelines*. *Chest*. 141(2 Suppl):e185S-94S, 2012
48. Menzin J, Hoesche J, Friedman M, Nichols C, Bergman GE, Crowther M, **Garcia D**, Jones C. Failure to correct International Normalized Ratio and mortality among patients with warfarin-related major bleeding: an analysis of electronic health records. *J Thromb Haemost*. 10(4):596-605, 2012
49. **Garcia DA**, Crowther MA. Reversal of warfarin: case-based practice recommendations. *Circulation*. 125(23):2944-7, 2012
50. Kaatz S, Kouides PA, **Garcia DA**, Spyropoulos AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. *Am J Hematol*. 87 Suppl 1:S141-5, 2012
51. Witt DM, Delate T, **Garcia DA**, Clark NP, Hylek EM, Ageno W, Dentali F, Crowther MA. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. *Arch Intern Med*. 172(19):1484-1491, 2012
52. Siegal DM, **Garcia D**. Anticoagulants in cancer. *J Thromb Haemost*. 10: 2230-41, 2012
53. **Garcia D**, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. *J Thromb Haemost*. 11: 245-52, 2013
54. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, **Garcia D**, Ezekowitz J, Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. *Eur Heart J*. 34(31):2464-71, 2013
55. **Garcia D**, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. *Blood*. 122(5):817-24, 2013

56. Witt DM, Delate T, Clark NP, **Garcia DA**, Hylek EM, Ageno W, Dentali F, Crowther MA. Nonadherence with INR Monitoring and Anticoagulant Complications. *Thromb Res.* Aug;132(2):e124-30. 2013
57. **Garcia D**, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. *Am Heart J.* 166(3):549-58, 2013.
58. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, **Garcia D**, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB. Efficacy and Safety of Apixaban in Patients Following Cardioversion for Atrial Fibrillation: Insights from the ARISTOTLE trial. *J Am Coll Cardiol.* Mar 25;63(11):1082-7. 2014
59. Clark NP, Delate T, Riggs CS, Witt DM, Hylek EM, **Garcia DA**, Ageno W, Dentali F, Crowther MA; Warfarin interactions with antibiotics in the ambulatory care setting. *JAMA Intern Med.* Mar;174(3):409-16. 2014
60. Witt DM, Delate T, Hylek EM, Clark NP, Crowther MA, Dentali F, Ageno W, Martinez K, **Garcia D**. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. *Thromb Res.* 132: 770-775, 2013.
61. Siegal D, **Garcia D**, Crowther MA. How I Treat Target-Specific Oral Anticoagulant Associated Bleeding. *Blood.* Feb 20;123(8):1152-8. 2014
62. Imberti D, Dentali F, Ageno W, Crowther M, **Garcia D**, Huisman M, Rodeghiero F, D'Angelo A, Palareti G. Evidence and clinical judgment: vena cava filters. *Thromb Haemost.* Apr 1;111(4):618-24. 2014
63. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, **Garcia D**, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. *European Heart Journal.* Jul 21;35(28):1864-72. 2014
64. Libby E, **Garcia D**, Quintana D, Fekrazad MH, Bauman J, Ebaid A, Hromas R, Rabinowitz I, Wiggins C. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. *Leuk Lymphoma.* Dec;55(12):2850-7. 2014
65. Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, Sullivan RM, Hohnloser SH, **Garcia D**, Hanna M, Amerena J, Harjola VP, Dorian P, Avezum A, Keltai M, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. *J Am Coll Cardiol.* Oct 14;64(15):1541-50. 2014
66. Cuker A, Siegal DM, Crowther MA, **Garcia D**. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. *J Am Coll Cardiol.* Sep 16;64(11):1128-39. 2014
67. **Garcia D**, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. *Blood.* 2014 Dec 11;124(25):3692-8.
68. Nutescu EA, Wittkowsky AK, Witt DM, Kaatz S, Ansell J, Burnett A, **Garcia D**, Lopes RD, Oertel L, Schnurr T, Streiff M, Wirth D, Crowther M. Integrating electronic health records in the delivery of optimized anticoagulation therapy. *Ann Pharmacother.* 49(1):125-6. 2015
69. van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Décousus H, **Garcia D**, Gibbs



- H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso MA, Büller HR, Raskob GE. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. *Thromb Haemost.* 2015 Nov 25;114(6):1268-76.
70. Witt DM, Clark NP, Martinez K, Schroeder A, **Garcia D**, Crowther MA, Ageno W, Dentali F, Ye X, Hylek E, Delate T. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. *Thromb Res.* 2015 Nov;136(5):1040-4.
  71. Samuelson B, Chai-Adisaksopha C, **Garcia D**. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. *J Thromb Thrombolysis.* 2015 Nov;40(4):474-9.
  72. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, **Garcia D**, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL; BRIDGE Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. *N Engl J Med.* 2015 Aug 27;373(9):823-33.
  73. Samuelson BT, Glynn E, Holmes M, White AA, Martin DB, **Garcia D**. Use of a computer-based provider order entry (CPOE) intervention to optimize laboratory testing in patients with suspected heparin-induced thrombocytopenia. *Thromb Res.* 2015 Nov;136(5):928-31.
  74. Samuelson BT, Vesely SK, Chai-Adisaksopha C, Scott BL, Crowther M, **Garcia D**. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. *Blood Coagul Fibrinolysis.* 2016 Sep;27(6):648-52.
  75. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, **Garcia DA**, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. *J Thromb Thrombolysis.* 2016 Jan;41(1):206-32.
  76. Ageno W, Beyer-Westendorf J, **Garcia DA**, Lazo-Langner A, McBane RD, Paciaroni M. Guidance for the management of venous thrombosis in unusual sites. *J Thromb Thrombolysis.* 2016 Jan;41(1):129-43.
  77. Khorana AA, Carrier M, **Garcia DA**, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. *J Thromb Thrombolysis.* 2016 Jan;41(1):81-91.
  78. Samuelson BT, Gernsheimer T, Estey E, **Garcia DA**. Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia. *Thromb Res.* 2016 May;141:104-5.
  79. Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, Ezekowitz MD, Fanikos J, Fareed J, **Garcia D**, Giugliano RP, Goldhaber SZ, Granger C, Healey JS, Hull R, Hylek EM, Libby P, Lopes RD, Mahaffey KW, Mega J, Piazza G, Sasahara AA, Sorond FA, Spyropoulos AC, Walenga JM, Weitz JI. North American Thrombosis Forum, AF Action Initiative Consensus Document. *Am J Med.* 2016 May;129(5 Suppl):S1-S29
  80. Burnett AE, Bowles H, Borrego M, Montoya TN, **Garcia DA**, Mahan C. Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory. *J Thromb Thrombolysis.* 2016 Nov;42(4):471-8.
  81. Whitlock RP, Whitlock R, Fordyce CB, Midei MG, Ellis D, **Garcia D**, Weitz JI, Canafax DM, Albrecht D, Milner PG. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial. *Thromb Haemost.* 2016 Aug 1;116(2):241-50.
  82. Dentali F, Crowther M, Galli M, Pomero F, **Garcia D**, Clark N, Spadafora L, Witt DM, Ageno W; WARPED Investigators. Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. *Semin Thromb Hemost.* 2016 Sep;42(6):671-81.

83. Schünemann HJ, Ventresca M, Crowther M, Briel M, Zhou Q, **Garcia D**, Lyman G, Noble S, Macbeth F, Griffiths G, DiNisio M, Iorio A, Beyene J, Mbuagbaw L, Neumann I, Van Es N, Brouwers M, Brozek J, Guyatt G, Levine M, Moll S, Santesso N, Streiff M, Baldeh T, Florez I, Gurunlu Alma O, Solh Z, Ageno W, Marcucci M, Bozas G, Zulian G, Maraveyas A, Lebeau B, Buller H, Evans J, McBane R, Bleker S, Pelzer U, Akl EA. Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. *BMJ Open*. 2016 Apr 29;6(4):e010569.
84. Li W, **Garcia D**, Cornell RF, Gailani D, Laubach J, Maglio ME, Richardson PG, Moslehi J. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. *JAMA Oncol*. 2017 Jul 1;3(7):980-988.
85. Samuelson BT, Cuker A, Siegal DM, Crowther M, **Garcia DA**. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. *Chest*. 2017 Jan;151(1):127-138.
86. Boonyawat K, Caron F, Li A, Chai-Adisaksopha C, Lim W, Iorio A, Lopes RD, **Garcia D**, Crowther MA. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. *J Thromb Haemost*. 2017 Jul;15(7):1322-1333.
87. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, **Garcia DA**, Hylek EM, Hanna M, Wallentin L, Gersh BJ, Douglas PS, Alexander JH, Lopes RD. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. *Am J Med*. 2017 Dec;130(12):1440-1448.
88. Samuelson Bannow BT, Walter RB, Gernsheimer TB, **Garcia DA**. Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. *J Thromb Thrombolysis*. 2017 Nov;44(4):442-447.
89. Li A, Khalighi PR, Wu Q, **Garcia DA**. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. *J Thromb Haemost*. 2018 Jan;16(1):164-169.
90. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, **Garcia D**, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. *N Engl J Med*. 2018 Feb 15;378(7):615-624.
91. Li A, Davis C, Wu Q, Li S, Kesten MF, Holmberg LA, Gopal AK, **Garcia DA**. Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation. *Blood Adv*. 2017 Apr 27;1(12):707-714.
92. Rodger M, Langlois N, Middeldorp S, Kahn S, Sandset PM, Brighton T, Huisman MV, Meyer G, Konstantinides S, Ageno W, Morange P, **Garcia D**, Kreuziger LB, Young L, Key N, Monreal M, Jiménez D. Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. *Thromb Res*. 2018 Mar;163:128-131.
93. Li A, **Garcia DA**, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. *Thromb Res*. 2019 Jan; 173:158-163.
94. Rodger M, Langlois N, Middeldorp S, Kahn S, Sandset PM, Brighton T, Huisman MV, Meyer G, Konstantinides S, Ageno W, Morange P, **Garcia D**, Kreuziger LB, Young L, Key N, Monreal M, Jiménez D. Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. *Thromb Res*. 2018 Mar;163:128-131.
95. Wang T, Li A, **Garcia D**. Managing thrombosis in cancer patients *Res Pract Thromb Haemost*. 2018; May 1;2(3):429-438.

96. Nazha B, Pandya B, Cohen J, Zhang M, Lopes RD, **Garcia DA**, Sherwood MW, Spyropoulos AC. Periprocedural Outcomes of Direct Oral Anticoagulants vs. Warfarin in Non-Valvular Atrial Fibrillation: A Meta-analysis of Phase III Trials. *Circulation*. 2018 Oct 2;138(14):1402-1411.
97. **Garcia D**, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. *N Engl J Med*. 2018 May 24;378(21):2010-2021.
98. Castellucci LA, de Wit K, **Garcia D**, Ortel T, Le Gal G. Extended anticoagulation for unprovoked venous thromboembolism. *Res Pract Thromb Haemost*. 2018 Jun 6;2(3):529-534.
99. Poston JN, **Garcia DA**. The case against catheter-directed thrombolysis in patients with proximal deep vein thrombosis. *Blood Adv*. 2018 Jul 24;2(14):1803-1805.
100. Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, **Garcia D**, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Hernandez CR, Santamaria A, Schwocho L, Segers A, Verhamme P, Wang TF, Weitz JI, Zhang G, Zwicker JI, Büller HR, Raskob GE. "Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study." *Thromb Haemost*. 2018 Aug;118(8):1439-1449.
101. J Padnos L, **Garcia D**. "May-Thurner syndrome and thrombosis: A systematic review of antithrombotic use after endovascular stent placement." *Res Pract Thromb Haemost*. 2018 Oct 19;3(1):70-78.
102. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, **Garcia DA**, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" *N Engl J Med*. 2019 Feb 21;380(8):720-728.
103. Guimarães PO, Lopes RD, Alexander JH, Thomas L, Hellkamp AS, Hijazi Z, Hylek EM, Gersh BJ, **Garcia DA**, Verheugt FWA, Hanna M, Flaker G, Vinereanu D, Granger CB. "International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin." *J Thromb Thrombolysis*. 2019 Jul;48(1):27-34.
104. Li A, Manohar PM, **Garcia DA**, Lyman GH, Steuten LM. "Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer-associated thrombosis (CAT) in the United States." *Thromb Res*. 2019 May 16;180:37-42.
105. Chiasakul T, De Jesus E, Tong J, Chen Y, Crowther M, **Garcia D**, Chai-Adisaksotha C, R. Messe S, Cuker A. Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. *J Am Heart Assoc*. 2019;8: e012877.
106. Di Nisio M, van Es N, Carrier M, Wang TF, **Garcia D**, Segers A, Weitz J, Buller H, Raskob G. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. *J Thromb Haemost* 2019 Nov;17(11):1866-1874.
107. **Garcia DA**, Fisher DA, Mulder H, Wruck L, De Caterina R, Halvorsen S, Granger CB, Held C, Wallentin L, Alexander JH, Lopes RD. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Am Heart J*. 2019 Oct 31; 221:1-8.
108. Duong A, Sing S, Taketa C, Miske A, Segal E, **Garcia D**. Practical considerations for the use of direct oral anticoagulants in oncology patients. *J Oncol Pharm Pract*. 2020 Apr;26(3):692-702.
109. Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN, Gage BF, **Garcia DA**, Lyman GH, Sanfilippo KM. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. *J Natl Compr Canc Netw*. 2019 Jul 1;17(7):840-847.

110. Li A, Wu Q, Warnick G, Li S, Libby EN, **Garcia DA**, Lyman GH. The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. *Ann Hematol*. 2020 Jan;99(1):121-126.
111. Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, De Caterina R, Washam JB, Hylek EM, **Garcia DA**, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients with Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. *Circulation*. 2020 Jan 7;141(1):10-20.
112. Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, Gaddh M, **Garcia D**, Grosso MA, Kakkar AK, Mercuri MF, Middeldorp S, Royle G, Segers A, Shivakumar S, Verhamme P, Wang T, Weitz JI, Zhang G, Büller HR, Raskob G. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. *Thromb Res*. 2019 Nov 9; 185:13-19.
113. Butt JH, Li A, Xian Y, Peterson ED, **Garcia D**, Torp-Pedersen C, Køber L, Fosbøl EL. Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. *Am Heart J*. 2019 Oct; 216:117-124.
114. Li A, Kuderer NM, **Garcia DA**, Khorana AA, Wells PS, Carrier M, Lyman GH. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. *J Thromb Haemost*. 2019 Dec;17(12):2141-2151.
115. Khalighi PR, Martens KL, White AA, Li S, Silgard E, Frieze D, **Garcia DA**, Li A. "Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification." *J Oncol Pharm Pract*. 2020 Apr;26(3):529-535.
116. Li A, Carlson JJ, Kuderer NM, Schaefer JK, Li S, **Garcia DA**, Khorana AA, Carrier M, Lyman GH. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. *Cancer*. 2020 April; 126(8):1736-1748.
117. Ortel T, Meleth S, Catellier D, Crowther M, Erkan D, Fortin P, **Garcia D**, Haywood N, Kosinski A, Levine S, Phillips M, Whitehead N. Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. *J Thromb Haemost*. 2020 Sept; 18(9): 2274-2286.
118. May JE, Irelan PC, Boedeker K, Cahill E, Fein S, **Garcia DA**, Hicks LK, Lawson J, Lim MY, Morton CT, Rajasekhar A, Shanbhag S, Zumberg MS, Plovnick RM, Connell NT. Systems-based hematology: highlighting successes and next steps. *Blood Adv*. 2020 Sep 22;4(18):4574-4583.
119. Schünemann H, Ventresca M, Crowther M, Briel M, Zhou Q, Noble S, Macbeth F, Griffiths G, **Garcia D**, Lyman G, Di Nisio M, Iorio A, Mbuagbaw L, Neumann I, van Es N, Brouwers M, Guyatt G, Streiff M, Marcucci M, Baldeh T, Florez I, Alma O, Solh Z, Bossuyt P, Kahale L, Ageno W, Bozas G, Büller H, Lebeau B, Lecumberri R, Loprinzi C, McBane R, Sideras K, Maraveyas A, Pelzer U, Perry J, Klerk C, Agnelli G, Akl E. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. *Lancet Haematol* 2020; 7: e746–55.
120. Hill JB, **Garcia D**, Crowther M, Savage B, Peress S, Chang K, Deitelzweig S. Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study. *Blood Adv*. 2020 Nov 10;4(21):5373-5377.
121. Martens KL, da Costa WL, Amos CI, Davis C, Kesten M, Lee SJ, Zakai NA, **Garcia DA**, Li A. HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. *Blood Adv*. 2021 Jan 12;5(1):167-175.
122. Martens KL, Amos CI, Hernandez CR, Kebriaei P, da Costa WL Jr, Basom R, Davis C, Kesten M, Carrier M, **Garcia DA**, Lee SJ, Li A. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. *Am J Hematol*. 2021 Sep 1;96(9):1137-1146. Epub 2021 Jun. PMID: 34097772

123. Tritschler T, Salvatore SP, Kahn SR, **Garcia D**, Delluc A, Kraaijpoel N, Langlois N, Girard P, Le Gal G. *J Thromb Haemost.* 2021 Oct;19(10):2514-2521. Epub 2021 Aug. PMID: 34255928.
124. Bosch FTM, Mulder FI, Huisman MV, Zwicker JI, Di Nisio M, Carrier M, Segers A, Verhamme P, Middeldorp S, Weitz JI, Grosso MA, Duggal A, Büller HR, Wang TF, **Garcia D**, Kamphuisen PW, Raskob GE, van Es N. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. *J Thromb Haemost.* 2021 Aug. Online ahead of print. PMID: 34455706
125. Jiang D, Lim W, Crowther MA, **Garcia D**. A systematic review of the association between anti-beta-2 glycoprotein I antibodies and APS manifestations. *Blood Adv.* 2021 Oct 26;5(20):3931-3936. PMID: 34547773
126. Jiang D, Portuguese AJ, Weatherford A, **Garcia D**, Gernsheimer T. Platelet trends after Covid-19 vaccination in patients with chronic or persistent immune thrombocytopenia. *Am J Hematol.* 2021 Dec 1;96(12):E472-E474. PMID: 34619804
127. Li A, Martens KL, Nguyen D, Basom R, Rondon G, Jin S, Young E, Amos CI, Lee SJ, Davis C, **Garcia D**, Champlin R, Shpall E, Kebriaei P, Rojas Hernandez C. External validation of the HIGH-2-LOW model: A predictive score for venous thromboembolism after allogeneic transplant. *Am J Hematol.* 2022 Jun 1;97(6):740-748. PMID: 35266218
128. Barnes GD, Burnett A, Allen A, Ansell J, Blumenstein M, Clark NP, Crowther M, Dager WE, Deitelzweig SB, Ellsworth S, **Garcia D**, Kaatz S, Raffini L, Rajasekhar A, Beek AV, Minichiello T. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. *J Thromb Thrombolysis.* 2022 Aug;54(2):197-210. PMID: 35579732
129. Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, **Garcia D**, Garonzik S, Lopes RD, Mahaffey KW, Matsuda K, Middleton JP, Rymer JA, Sands GH, Thadhani R, Thomas KL, Washam JB, Winkelmayr WC, Granger CB; RENAL-AF Investigators. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. *Circulation.* 2022 Dec 6;146(23):1735-1745. PMID: 36335914
130. Coston TD, Vaidya S, Badulak J, **Garcia D**, Keel S, Mulligan M, Ramos KJ, Kapnadak SG. Inferior Vena Cava Obstruction Complicating Remote Venovenous Extracorporeal Membrane Oxygenation Bridge to Lung Transplantation. *Chest.* 2022 Jul;162(1):e5-e8. PMID: 35809951
131. da Costa WL Jr, Guffey D, Oluyomi A, Bandyo R, Rosales O, Wallace CD, Granada C, Riaz N, Fitzgerald M, **Garcia D**, Carrier M, Amos CI, Flowers CR, Li A. Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. *Am J Hematol.* 2022 Aug;97(8):1044-1054. PMID: 35638475
132. Pagano MB, Foroutan F, Goel R, Allen ES, Cushing MM, **Garcia D**, Hopkins CK, Klein K, Raval JS, Cohn CS. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB. *Transfusion.* 2022 Aug;62(8):1652-1661. PMID: 35834523
133. Al-Khatib SM, Wojdyla DM, Granger CB, Wallentin L, **Garcia D**, Hijazi Z, Held C, Alexander JH, Vinereanu D, Flaker GC, Hylek EM, Lopes RD. Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. *Circulation.* 2022 Sep 20;146(12):958-960. PMID: 36121911
134. Khairani CD, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller SC, Cortes-Hernandez J, Connors JM, Kanthi Y, Krumholz HM, Middeldorp S, Falanga A, Cushman M, Goldhaber SZ, **Garcia D**, Bikdeli B. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. *J Am Coll Cardiol.* 2023 Jan 3;81(1):16-30. PMID: 36328154

135. Li A, La J, May SB, Guffey D, da Costa WL Jr, Amos CI, Bandyo R, Milner EM, Kurian KM, Chen DCR, Do NV, Granada C, Riaz N, Brophy MT, Chitalia V, Gaziano JM, **Garcia D**, Carrier M, Flowers CR, Zakai NA, Fillmore NR. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. *J Clin Oncol*. 2023 Jun 1;41(16):2926-2938.PMID: 36626707
136. Avery J, Guffey D, Ma S, Basom R, Lee S, **Garcia D**, Rojas Hernandez C, Li A, Martens K. Risks factors and outcomes for isolated catheter-related deep venous thrombosis in patients undergoing allogeneic hematopoietic stem cell transplantation. *Thromb Res*. 2023 Sep: 229:1-6. PMID: 37356171
137. Kanack AJ, Athale J, Leger RR, Saadalla A, Heikal NM, Chen D, Garcia DA, Singh R, Pruthi RK, Padmanabhan A. "Autoimmune HIT" antibodies in diagnostic samples are a potential artifact and not associated with more severe outcomes. *Blood Adv*. 2023 Aug 22;7(16):4431-4434.
138. Zakai NA, Wilkinson K, Sparks AD, Packer RT, Koh I, Roetker NS, Repp AB, Thomas R, Holmes CE, Cushman M, Plante TB, Al-Samkari H, Pishko AM, Wood WA, Masias C, Gangaraju R, Li A, **Garcia D**, Wiggins KL, Schaefer JK, Hooper C, Smith NL, McClure LA. *J Thromb Haemost*. 2023 Oct 31:S1538-7836(23)00784-5. PMID: 37918635
139. Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, ..., **Garcia D**, ..., Erkan D. "2023 ACR/EULAR antiphospholipid syndrome classification criteria." *Arthritis Rheumatol*. 2023 Oct;75(10):1687-1702. PMID: 37635643
140. Marx CE, Schenker C, Xu Y, Salvatore SP, Kahn SR, **Garcia D**, Delluc A, Kraaijpoel N, Langlois N, Girard P, Le Gal G, Tritschler T. "Accuracy and interrater agreement of death event adjudications by physician trainees: validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort" *J Thromb Haemost*. 2023 Oct;21(10):2908-2912.PMID: 37517478
- 141.

### Book chapters

1. **Garcia D**. Crowther M. Deep vein thrombosis. Chapter in *Hospital Medicine*, 2<sup>nd</sup> Edition Lippincott, Williams and Wilkins – Editor, Wachter; 2005
2. **Garcia D**. Cohen J, Burnett A. Hemorrhagic complications of anticoagulants in hospitalized patients. Chapter in *Inpatient Anticoagulation*, 1<sup>st</sup> Edition Wiley-Blackwell – Editor, Fang; 2011
3. **Garcia D**. MacIndoe C. VTE prevention. Chapter in *Textbook of Neurointensive Care*. Springer – Editor, Layon et al 2013.
4. Samuelson, B. **Garcia D**. Thromboembolism in MPN Chapter in *Managing Myeloproliferative Neoplasms: A Case-Based Approach*. Cambridge University Press - Editors, Mesa and Harrison; 2016.
5. **Garcia D**, Ageno W, Crowther M. The Direct Oral Anticoagulants. Chapter in *Practical Hemostasis and Thrombosis, Third Edition*. Wiley & Sons – Editors, Key, Makris and Lillicrap.

### Books

1. Antiplatelet and Anticoagulation Therapy. Ferro A and **Garcia D**. Editors. 1<sup>st</sup> Edition. 2013. ISBN: 978-1-4471-4296-6 (Print).

2. Consultative Hemostasis and Thrombosis. Kitchens, Kessler, Konkle, Streiff, **Garcia**.  
Editors. Fourth Edition. 2018.

**Other publications**

1. **Garcia D.** Commentary on: Below-knee elastic compression stockings reduced development of the post-thrombotic syndrome in proximal deep venous thrombosis. *ACP J Club.* 142(1):7, 2005
2. Ageno W, Squizzato A, **Garcia D**, Imberti D. Epidemiology and risk factors of venous thromboembolism. *Semin Thromb Hemost.* 32(7):651-8, 2006
3. **Garcia D**, Hylek E. Antithrombotic Therapy in Atrial Fibrillation. *Clin Geriatr Med.* 22(1):155-66; 2006
4. **Garcia D**, Hylek E. Commentary on: Development of a contemporary bleeding risk model for elderly warfarin recipients. *ACP J Club.* 146(2):52; 2007
5. **Garcia D**, Spyropoulos A. Update in the treatment of venous thromboembolism. *Semin Respir Crit Care Med.* 29:40-46, 2008
6. **Garcia D**, Hylek E. Reducing the risk for stroke in patients who have atrial fibrillation. *Cardiol Clin.* 26:267-275, 2008
7. **Garcia D.** Duration of anticoagulant therapy for patients with venous thromboembolism. *Thromb Res.* 123 Suppl 1:S62-4, 2008
8. **Garcia D.** Warfarin and pharmacogenomic testing: the case for restraint. *Clin Pharmacol Ther.* 84(3):303-5, 2008
9. **Garcia D.** ACP Journal Club. Review: D-dimer levels predict risk for recurrent VTE after anticoagulant therapy is stopped. *Ann Intern Med.* 150(4):JC2-14, 2009
10. **Garcia D**, Hylek E. Warfarin pharmacogenetics. *N Engl J Med.* 360(23):2474, 2009
11. **Garcia D.** Novel anticoagulants and the future of anticoagulation. *Thromb Res.* 123 Suppl 4:S50-5. Review, 2009
12. **Garcia DA.** Rethinking warfarin reversal. *Blood.* 116(5):675-6, 2010
13. **Garcia DA.** Current therapeutic strategies and future perspectives for the treatment of venous thromboembolism. *Curr Pharm Des.* 16(31):3475, 2010
14. **Garcia DA.** Hemorrhagic complications of anticoagulants in hospitalized patients. Chapter in *Inpatient Anticoagulation*, First Edition Wiley-Blackwell – Editor, Fang; 2011
15. **Garcia DA**, Granger CB. Anticoagulation, novel agents, and procedures: can we pardon the interruption? *Circulation.* 126(3):255-7, 2012
16. **Garcia D.** ACP Journal Club. After a first proximal DVT, compression stockings did not prevent the post-thrombotic syndrome. *Ann Intern Med.* Apr 15; 160(8):JC7. 2014
17. **Garcia D.** VTE risk and family history: provocative findings. *Blood.* Sep 25; 124(13):2011. 2014.
18. Kim B, **Garcia DA.** What is the role of hemodialysis for dabigatran-associated major bleeding? *Hematology Am Soc Hematol Educ Program.* 2014 Dec 5;2014(1):514-7
19. Li A, Lopes RD, **Garcia DA.** Use of Direct Oral Anticoagulants in Special Populations. *Hematol Oncol Clin North Am.* 2016 Oct;30(5):1053-71.
20. **Garcia D.** ACP Journal Club. Review: Compression stockings reduce symptomless DVT in airline passengers. *Ann Intern Med.* 2017 Jan 17;166(2).
21. **Garcia D.** Hybrid Strategy to Prevent Venous Thromboembolism after Joint Arthroplasty. *N Engl J Med.* 2018 Feb 22;378(8):762-763.
22. Diep R, **Garcia D.** Does aspirin prevent venous thromboembolism? *Hematology.* 2020 Dec 4;2020(1):634-641. PMID: 33275727
23. Diep R, **Garcia D.** In COVID-19, therapeutic vs. prophylactic anticoagulation did not improve clinical outcomes and increased bleeding. *Ann Intern Med.* 2021 Oct;174(10):JC112. PMID: 34606319
24. Bikdeli B, **Garcia DA.** In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d. *Ann Intern Med.* 2022 Feb;175(2):JC17.



**Selected invited presentations (since 2010)**

“Update in the Antiphospholipid syndrome” April 2023; Anticoagulation Forum Biennial Meeting San Francisco, CA.

“Thrombosis and Anticoagulation” February 2023, Highlights of ASH Mediterranean, Istanbul, Turkey.

“Thrombosis and Anticoagulation” January 2023, Highlights of ASH North America, Seattle, WA.

“Compensation Models in Hematology” December 2022, ASH Annual Meeting New Orleans, LA.

“Update in the Antiphospholipid syndrome” January 2022, Hematology Grand Rounds, University of Miami

“Best of ASH – Non-Malignant Hematology” February 2019, Highlights of ASH Asia-Pacific, Bangkok, Thailand.

“Update in Cancer-associated Thrombosis” July 2017 International Society of Thrombosis and Hemostasis, Berlin, Germany.

“Duration of Anticoagulant Therapy for Patients with Antiphospholipid Antibodies“ June 2015, European Hematology Association, Vienna, Austria.

“An Update in Thrombosis and Anticoagulation” April 2015, Highlights of ASH Latin America, Cartagena, Colombia.

“Skating on thin ice with Blood Thinners” December 2014, American Society of Hematology Annual Meeting, San Francisco, CA.

“The Target Specific Anticoagulants” November 2014, Brazilian Congress of Hematology and Hemotherapy, November 2014, Florianopolis, Brazil.

“Evidence-based Practice Guidelines: Balancing Rigor with User-friendliness” December 2013; American Society of Hematology Annual Meeting, New Orleans, LA.

“Treatment of Bleeding and Thromboembolism: The Old and the New” October 2014; International Symposium on Thrombosis and Anticoagulation, São Paulo, Brazil.

“An Update on the Targeted Oral Anticoagulants” June 2014; Internal Medicine Grand Rounds Memorial Sloan Kettering Cancer Center, New York, New York.

“Urgent Surgery with the Novel Anticoagulants” November 2013; American Heart Association Annual Meeting, Dallas, Texas.

“An Update in Cancer and Thrombosis” October 2013; Grupo Cooperativo Latino Americano de Hemostasia y Trombosis, Cancún, Mexico.

“What’s New in Bleeding and Clotting Disorders” August 2012; Mayo Clinic Hematology/Oncology Review Course, Amelia Island, FL.

“Changes to the ACCP Guidelines on the Prevention of VTE after Non-Orthopedic Surgery” June 2012; Groupe Interdisciplinaire Trousseau sur les Antithrombotiques, Paris, France.

“The Pharmacology of the New Anticoagulants”. April 2012; American College of Physicians Annual Meeting, New Orleans, LA.

“Cancer and Venous Thromboembolism” April 2012; Curso Internacional de Avances en Trombosis y Hemostasia, Pontificia Universidad Católica de Chile, (Santiago).

“The Future of Anticoagulation”. March 2012; Johns Hopkins University Internal Medicine Grand Rounds, Baltimore, MD.

“The Future of Anticoagulation”. January 2012; University of Washington Hematology Grand Rounds, Seattle, WA.

“The New Oral Anticoagulants”. November 2011; Stanford University School of Medicine: Safe Management of Anticoagulation Therapy, Palo Alto, CA

“The Future of Anticoagulation”. November 2011; Mayo Clinic Internal Medicine Grand Rounds, Scottsdale, AZ

“A Debate on Bleeding Risk Models”. October 2011; International Symposium on Thrombosis and Anticoagulation, Salvador, Brazil

“Cancer-Associated Thrombosis”. September 2011; McMaster University: Symposium on Thromboembolism, Hamilton, ON, Canada

“Thrombosis and Anticoagulation”. April 2011; Highlights of ASH Latin America, Punta Del Este, Uruguay.

“Thrombosis and Anticoagulation”. January 2011; Highlights of ASH North America, San Diego, CA

“Personalized Medicine: Pharmacogenomics of Clopidogrel and Warfarin”. December 2010; American Society of Hematology Annual Meeting, Orlando, FL

“The Vitamin K Antagonists in 2010 – an Update” October 2010; International Symposium on Thrombosis and Anticoagulation, São Paulo, Brazil.